FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Welichem Biotech

Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis

15-Dec-2009 - Welichem announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study. The objectives of the trial are to evaluate the efficacy of the creams ...

atopic dermatitis clinical trials phase IIb studies

Welichem Announces Appointment of New CFO

13-Jan-2009 - Welichem Biotech Inc. announced the appointment of Yue Zhao as Chief Financial Officer (CFO) of the Company, effective immediately. Ms. Yue brings in more than 16 years' financial and accounting experience from private and public companies. Ms. Yue obtained her Certified General Accountant ...

Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema

27-Feb-2008 - Welichem Biotech Inc. announced that Health Canada approved the Company's Clinical Trial Application (CTA) to begin a Phase IIa Clinical Trial of its anti-inflammatory drug candidate, WBI-1001, on atopic dermatitis (a type of eczema). The Company will initiate its Phase IIa Clinical Trial of ...

anti-inflammatory drugs atopic dermatitis clinical trials +1

Welichem Biotech Inc. granted Australian Patent for compounds treating autoimmune/inflammatory diseases

21-Sep-2005 - Welichem Biotech Inc. announced that the Australian Patent Office has granted the Company a patent (No.780700) covering compounds in the WBI-1000 series that are useful in the treatment of inflammatory/auto-immune diseases such as psoriasis and inflammatory bowel disease. A total of 16 claims ...

autoimmune diseases China diseases +4

Welichem Biotech Inc. announces changes to Board of Directors

23-Aug-2005 - Welichem Biotech Inc. announced changes to its Board of Directors. The Company increased the number of Directors on its Board from six to seven and appointed Mr. Weihe Wang, a representative from Celestial Pharmaceuticals (Shenzhen) Ltd, to the Board. Mr. Wang Weihe is an entrepreneur with broad ...

drug development food